

11. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 8, ~~any one of claims 8-10~~ which is an orally administrable medicament.

12. (Currently amended) ~~A medicament~~ The therapeutic formulation as claimed in claim 11, wherein the medicament ~~which~~ is a syrup, mouthwash, gargle, toothpaste or mouth spray.

13. (Currently amended) ~~A medicament~~ The therapeutic formulation as claimed in claim 11, wherein the medicament ~~which~~ is in a unit dosage form.

14. (Currently amended) ~~A medicament~~ The therapeutic formulation as claimed in claim 12, wherein the medicament ~~which~~ is a lozenge or capsule ~~containing a unit dose of an organism which can express a protein as claimed in any one of claims 1-6~~.

15. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 8 ~~any one of claims 8-11~~ in which said protein ~~or organism~~ is included in a food or drink.

16. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 15 in which said food or drink is a dairy product based food or drink.

17. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 16 in which said protein ~~or organism~~ is included in milk powder, milk biscuits, milk, yoghurt or cheese.

18. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 16 in which said protein ~~or organism~~ is included in a flavoured milk.

19. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 8, ~~any one of claims 8-10~~ in which said protein ~~or organism~~ is included in a confectionery.

20. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 19 in which said confectionery is a chewing gum.

21. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 8, ~~any one of claims 9-20~~ which further comprises one or more secondary antibacterial agents.

22. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 21 in which said secondary antibacterial agent(s) are selected from bacteriocin-like inhibitory substance(s) (BLIS).

23. (Currently amended) ~~[[A]]~~The therapeutic formulation as claimed in claim 20 which includes one or more both of Salivaricin A, ~~[[an]]~~ a microorganism which can express Salivaricin A, ~~the~~ an antibacterial protein which has the amino acid sequence of SEQ ID NO:5,

or ~~[[an]]~~ microorganism which ~~can~~ expresses the antibacterial protein which has the amino acid sequence of SEQ ID NO:5.

24-26. (Cancelled)

27. (Currently amended) ~~An~~ A transgenic microorganism, in substantially pure form, which includes a polynucleotide which:

- a) encodes a protein as claimed in any one of claims 1, 3, 4 or 6~~[[6]]~~; or
- b) comprises the coding sequence of SEQ ID NO:2; ~~or~~
- ~~c) encodes a protein as claimed in any one of claims 1-6, comprising the DNA sequence which encodes an antibacterial protein as claimed in claim 1, which is part of the genome of S. salivarius strain K12, on deposit at Deutsche Sammlung von Mikroorganismen Und Zellkulturen GmbH, Braunschweig, Germany, accession number DSM 13084.~~

28. (Cancelled)

29. (Currently amended) ~~[[An]]~~ The microorganism as claimed in claim 27 which is a *S. salivarius* organism.

30. (Currently amended) A biologically pure culture of *S. salivarius* strain K12 or a microorganism therefrom, on deposit at Deutsche Sammlung von Mikroorganismen Und Zellkulturen GmbH, Braunschweig, Germany, accession number DSM 13084.

31. (Currently amended) A biologically pure culture of *S. salivarius* strain K30 or a microorganism therefrom on deposit at Deutsche Sammlung von Mikroorganismen Und Zellkulturen GmbH, Braunschweig, Germany, accession number DSM 13085.

32. (Currently amended) A therapeutic formulation which includes *S. salivarius* strain K12 or *S. salivarius* strain K30 as identified in claim 30 or claim 31 or the transgenic microorganism as claimed in claim 27.

33. (Currently amended) A method of treating an individual to at least inhibit growth of harmful streptococcal bacteria in the upper respiratory tract, comprising the step of administering an effective amount of ~~[[a]]~~ the protein as claimed in any one of claims 1, 3, 4 or 6, the therapeutic formulation as claimed in claim 8, or the microorganism as claimed in any one of claims 27, 30 or 31~~[[6]]~~ orally to said individual.

34-35. (Cancelled)

36. (Currently amended) ~~[[A]]~~ The method as claimed in claim ~~35~~ 33, wherein said microorganism is administered as part of a medicament, a food or drink or a confectionery.

37. (Cancelled)

38. (Currently amended) ~~[[A]]~~The method as claimed in claim 33 ~~any one of claims 33-37~~ which includes a preliminary step of pre-treating said individual to at least reduce the bacterial population present in the upper respiratory tract.

39. (Currently amended) ~~[[A]]~~The method as claimed in claim 38 wherein said pre-treatment comprises the step of administering an antibiotic orally to said individual.

40-46. (Cancelled)

47. (New) The therapeutic formulation as claimed in claim 32 which is a lozenge or capsule.